Pharma & COVID-19: Winners, losers, prospects
EPHA #A2MDialogues
19 November 2020
16:00-17:00 CET
online
Our third dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
Is the affordability debate in Europe changing in the light of COVID-19?
Who are the big winners and losers?
From the onset of the COVID-19 pandemic, governments turned to the pharmaceutical sector for answers and solutions. Almost a year later, we look at how the present pandemic has reshaped the dynamics within the sector, as well as the power balance between this diverse business sector and European governments. What are the trends for the near future?
We will hear from a venture capitalist investing in pharma, a leading access to medicines advocate, an expert in the science and economics of drug R&D, and the advocacy director of an alternative drug development model.
Panelists
Andrew Elder
Deputy Managing Partner
Albion VC
Dr Els Torreele
Visiting Policy Fellow, Institute for Innovation and Public Purpose
Jack Scannell
Innogen Associate & Honorary Fellow, School of Social and Political Science
University of Edinburgh
Michelle Childs
Director of Policy Advocacy
DNDi
Moderated by
Yannis Natsis,
Policy Manager, Universal Access to Affordable Medicines
European Public Health Alliance
Join our panelists to discuss
Is pharma benefiting from the circumstances created by the pandemic?
What are the risks for governments and the industries?
What have been the key opportunities for industry from the pandemic?
What opportunities and risks do investors see?
Is self-sufficiency the right path for Europe?
Find out more about the other #A2MDialogues in the series below
Unleashing meaningful innovation through regulatory reform
19 October 2020
The EU's IP strategy: Enabler or barrier?
27 October 2020
The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines
25 November 2020
16:00-17:00 CET